Regarding Official Response from J-mit

On August 16 and 17, 2025, Triplex Therapeutics Inc. (CEO: Dr. Takamitsu Yano) submitted opinion statements to AMED, MHLW, PMDA, and the Japanese Society for Mitochondrial Research and Medicine, raising concerns regarding the safety and efficacy of PI polyamides targeting the A3243G mutant mitochondrial DNA designed by the third party research group.

On August 20, 2025, we received an official response from the Secretariat of the Japanese Society for Mitochondrial Research and Medicine (J-mit).

The Society acknowledged our submission as “an academically important perspective” and confirmed that it will be forwarded to the selection committee for consideration and decision .

While the Society does not take a position on validating or invalidating specific research, it has explicitly affirmed its role as a neutral platform for academic exchange, ensuring fair handling of our submission.

Triplex Therapeutics will continue to place patient safety and scientific integrity at the forefront, advancing research in collaboration with academia, regulatory authorities, and the international community.

Every step we take is dedicated to protecting the lives and futures of patients and their families.